A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AD-227A and AD-227B Combination Treatment in Patients with Essential Hypertension
Overview
- Phase
- Phase 3
- Intervention
- AD-227C
- Conditions
- Essential Hypertension
- Sponsor
- Addpharma Inc.
- Enrollment
- 251
- Locations
- 1
- Primary Endpoint
- Change in MSSBP
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of co-administration of AD-227A and AD-227B in patients with essential hypertension
Detailed Description
Essential Hypertension
Investigators
Eligibility Criteria
Inclusion Criteria
- •Signed informed consent
- •Patients with Essential Hypertension
- •Other inclusions applied
Exclusion Criteria
- •Patient with Secondary Hypertension
- •Other exclusions applied
Arms & Interventions
Co-administration of AD-227A and AD-227C
AD-227A + Placebo of AD-227B + AD-227C
Intervention: AD-227C
Co-administration of AD-227A and AD-227C
AD-227A + Placebo of AD-227B + AD-227C
Intervention: Placebo of AD-227B
Co-administration of AD-227A and AD-227B
AD-227A + AD-227B + Placebo of AD-227C
Intervention: AD-227A
Co-administration of AD-227A and AD-227B
AD-227A + AD-227B + Placebo of AD-227C
Intervention: AD-227B
Co-administration of AD-227A and AD-227B
AD-227A + AD-227B + Placebo of AD-227C
Intervention: Placebo of AD-227C
AD-227A
AD-227A + Placebo of AD-227B + Placebo of AD-227C
Intervention: AD-227A
AD-227A
AD-227A + Placebo of AD-227B + Placebo of AD-227C
Intervention: Placebo of AD-227B
AD-227A
AD-227A + Placebo of AD-227B + Placebo of AD-227C
Intervention: Placebo of AD-227C
Co-administration of AD-227A and AD-227C
AD-227A + Placebo of AD-227B + AD-227C
Intervention: AD-227A
Outcomes
Primary Outcomes
Change in MSSBP
Time Frame: Baseline to Week8
Change from Baseline in Mean Sitting Systolic Blood Pressure